---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-023788"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:48:05.484698+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Whitehawk Q1 net income $73M on divestiture gain; cash $231M, expects $185M into 2028

## Summary
- Q1 2025 net income of $73.0M includes $87.4M gain from Aadi Sub divestiture; ex-gain net loss $14.4M.
- Revenue $7.1M from FYARRO sales through March 25, 2025, date of divestiture to Kaken for $102.4M.
- Cash and equivalents $231.1M at March 31, 2025 (vs $47.2M Dec 31, 2024) after closing $100M PIPE.
- Expects cash of ~$185M after transaction payments, funding operations into 2028.
- Oncology ADC pipeline: three assets targeting PTK7, MUC16, SEZ6; first IND on track for Q4 2025.

## SEC filing metadata
- accession: 0001628280-25-023788
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000162828025023788/0001628280-25-023788-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000162828025023788/aadi-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-023788
- JSON: https://secwatch.observer/filing/0001628280-25-023788.json
- Plain text: https://secwatch.observer/filing/0001628280-25-023788.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.